Prostate-specific antigen (PSA) is a 33-kDa single-chain glycoprotein produced by prostatic epithelium. 4 The primary structure of PSA was first described by Watt et al. [1] and shows a high degree of homology with serine proteases of the kallikrein family [2, 3] . PSA is a major protein in seminal plasma and shows chymotrypsin-like substrate specificity [4- June 25, 1996 ; accepted June 25, 1996. found in low concentrations (<2.5 jigfL) in male blood plasma but can be increased in conjunction with prostate cancer, benign prostatic hyperplasia (BPH), and surgical trauma to the prostate [7] [8] [9] .Monoclonal antibody (niAb)-based RIAs and ELISAs are used to measure PSA in serum. The results are used to screen for prostate cancer and monitor patients during treatment The PSA gene is a member of the human tissue kallikrein gene family referred to as serine proteases because the mechanism of proteolytic cleavage involves a serine residue at the active site [1, 12, 13] . PSA is a 6-kb gene product of chromosome 19 in the region of q 13.2-q 13.4 with 4 introns and 5 exons [14] . It has a >84% nucleotide sequence homology with human glandular kallikrein (hK2), and 73% homology with human pancreatic kallikrein (hKl), indicating a common ancestral gene [3, [15] [16] [17] [18] . Human serum kallikrein is not a member of this gene family and does not have a high degree of sequence homology to PSA. The amino acid homology with porcine pancreatic kallikrein (pKl) is59.6%. Previously all three gene products were renamed [15, 17] , as shown in Table 1 .
In serum, PSA can form stable complexes with two major serum protease inhibitors, a,-macroglobulin (AMG) and a1-antichymotrypsin (ACT) [20] [21] [22] .
When

PSA iscomplexed to
AMG it is thought to be completely encapsulated with no epitopes accessible for immunodetection [23] . However, when PSA is complexed to ACT, some epitopes proximal to the active site are masked while others are available for binding to anti-PSA antibodies [21] . Immunoassays involving antibodies directed against PSA epitopes that are masked by ACT will fail to detect this complex. The proportion of serum PSA cornplexed to ACT has heen found to be significantly higher with prostate cancer than with BPH. The ratio of free to complexed PSA, therefore, may be useful in distinguishing between prostatic cancer and BPH [21] [22] [23] . It is important, therefore, to determine if antibodies used to measure PSA in serum are recognizing free PSA, PSA-ACT, or both. In addition, several authors have recently discussed the importance of standardizing PSA assays, because many of the commercially available assays yield different PSA values [24] [25] [26] [27] [28] [29] [30] . In this paper, we attempt to identify and characterize the epitopes that are recognized by two anti-PSA mAbs. 
Purification of PSA.
A human prostate cancer cell line (LNcap) was used as a source of PSA. The cells were grown (standard media, 275 mm2 tissue culture flask) and the supernatant was collected and pooled every 3 to 5 days. The concentration of PSA in the unpurified supernatant was determined to be 0.9-1.5 irmg/L by ELISA. PSA was purified from I L of cell supernatant by using an affinity column with immobilized anti-PSA antibodies, B80 and B87. The column was made by first washing Sepharose 4B (1 g in 3.5 mL, cyanogen bromide activated) with 2 volumes of buffer (0.5 mol/L phosphate, pH 6.8). A mixture of B80 and B87 [10 mg in 3 mL of phosphate-buffered saline (PBS), pH 7.21 was dialyzed overnight against three changes of buffer. The antibodies were added to the Sepharose gel and gently agitated at room temperature. The amount of antibody remaining in solution was determined by monitoring the reaction mixture absorbance at 280 nm. The reaction was stopped when -90% of the antibody was bound. The column was then washed twice with PBS (10 mL), and ethanolamine (10 mL of 100 ninol/L in distilled water) was added to block any unbound reaction sites on the Sepharose (2 h at room temperature).
Before use, the mAb affinity column was washed twice (10 mL of 10 mmollL phosphate buffer, pH 6.4). Cell supernatant containing 1.5 mg/L PSA (1 L) was cycled for 24 h through the column with a peristaltic pump (1.7 mL/min) so that the total volume of supernatant passed through the column three times. After washing the column with buffer, the PSA was eluted with glycine (100 mmol/L, pH 2.5). Column fractions (0.5 mL) were collected into tubes containing buffer (50 .tL of 1 mol/L phosphate, pH 8.0) to neutralize the eluates. The protein concentration of each fraction was determined by measuring the absorbance at 280 nni and the appropriate fractions were pooled. After pooling, an ELISA was performed as described below to determine the concentration of purified PSA. The column, which can be reused, was washed (1 g/L sodium azide in 10 mmol/L phosphate) and stored at 4 #{176}C until needed. PSA eluted from the monoclonal affinity column in fractions 3 to 5 and a total of 1.37 mg of PSA was recovered from 1.5 L of supernatant. No remaining PSA was detected in the supernatant after affinity purification.
Preparation and analysis of PSA -ACT complex. The complex was prepared by using the method described by Lilja et al. [22] . Purified PSA (7 g) was added to purified ACT (50 g) in reaction buffer (50 iL of 50 mmol/L Tris-HC1, pH 7.8, with 0.1 molJL NaC1) and incubated for 6 h at 37 #{176}C. [31] . Microtiter wells were coated with mAb B87 (1 tg in PBS, 16 designated as the acid eluate, was collected. Both the ligand and acid eluates were amplified by infecting E. co/i cells with isolated phage, following procedures described in Christian et al. [32] . A second round of selection was performed as above.
IMMUNOLOGICAL SCREENING OF AFFINITY-SELECTED PHAGE
Affinity-selected phage particles were screened in an in situ immunological assay with phage-infected colonies [32] . Phage clones from the eluates were used to infect fresh cells. The cells were then grown in selective media (15 X The filters were washed again and incubated with TMB substrate for I h. The filters were then washed with distilled water and allowed to air dry overnight. Alternatively, filters with colonies from a second set of plates were incubated with B87 (1 mg in 100 mL of BSA-PBS) for 2 h at room temperature. After washing, the B87 filters were incubated with anti-mouse-HRPO
(1:1000 dilution in BSA-PBS, I h, room temperature). The filters were washed three times and incubated with TMB substrate. After 1 h the filters were washed with distilled water and allowed to air dry overnight. Positive clones were picked from the plates and amplified for sequencing.
Dideoxynucleotide sequencing was performed by using the Sequenase 2.0 system according to the manufacturer' s instructions.
MODELING OF PSA
A homology model of PSA was generated with INSIGHT II molecular modeling package (Biosym Technologies, San Diego, CA). The model was prepared by initially aligning the human PSA sequence against those of both porcine kallikrein (59% sequence identity) and rat tonin (54% sequence identity) by using structural alignment routines in the SEQSEE software [33] package (Biotools, Edmonton, AB, Canada). On the basis of these two alignments and on the quality of the available structural data, the x-ray structure of rat tonin (Brookhaven Protein Datahank accession code: ITON) was selected as the three-dimensional template for homology modeling the PSA structure. By using the sequence alignment produced by SEQ-SEE, the amino acid sequence of PSA was then substituted into that of tonin by using the Biopolymer module of INSIGHT II. The model was subjected to a brief period of conjugate gradient energy minimization to reduce unfavorable van der Waals contacts and torsional strain.
Results
ANALYSIS OF PSA-ACT COMPLEX
An immunoassay, shown in Fig. 3 , that is specific for the PSA-ACT complex was developed by using mnAbs B80 or B87 imnmobilized on microtiter plates and rabbit anti-ACT polyclonal antibody. Goat anti-rabbit antibody conjugated with Here again no differences were observed in the PSA values obtained, further confirming the PSA specificity of the mAbs. 
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Peptlde number In this assay, mAb B80 or B87 was used to capture PSA or PSA-ACTcomplex. Rabbit anti-ACT serum was used to detect any immobilized PSA-ACTcomplex. Both B80 and B87 were able to bind to PSA when complexed to ACT. Free PSA or ACT will not be detected in this assay. The difference in sensitivity of this assay to PSA and PSA-ACTcomplex is due to differences in reagents and assay format. The PSA assay involves two mAbs. whereas this assay involved rabbit anti-ACT polysera and anti-rabbit polysera to detect the complex. The concentration of complex is expressed as g/L of PSA. The assay was performed as described in Materials and Methods.
EPITOPE SCANNING WITH PSA-DERIVED HEXAPEPTIDES
To further identify the PSA epitopes bound by the two mAbs, we synthesized all the overlapping hexapeptides derived from the linear amino acid sequence on PSA. Fig. 4 shows the results of the screening of PSA sequence-derived hexapeptides with bsmAb B8OXHRPO. The PSA peptide number represents the position of the first amino acid in the hexapeptide relative to the PSA amino acid sequence. The data shown was not background subtracted and illustrates the low background signal from the hexapeptides, which do not bind to the bsmAb. In contrast, the A phage decapeptide display library [32] was used (4.4 X 10" particles in round 1) to identify peptides that would specifically bind to B80 or B87 and mnimic PSA epitopes. The Sepharose beads with immobilized antibody were used for the affinity selection, and the elution conditions were the same as those used for the affinity purification of PSA. This column, with 133 pmol of immobilized antibody, was able to bind 40 pmol of PSA without saturating (molar ratio of antibody to PSA of 3.3 to 1).
The molar ratio of antibody to phage was -70 to 1. The phage was eluted by incubating resin-bound phage with PSA and acid and separated by centrifugation, providing a yield of 3.1 X i#{248}
and 5 x l0 particles, respectively. The molar ratio of the immobilized antibody to the PSA used to elute the phage was -2.7 to 1. Functionally, this ratio would be much closer,since not all antibody combining sites would be available for PSA binding because CNBr-based coupling is a random linkage of macromolecules to the solid phase.
In addition, the affinity of the mAbs for PSA is high (i.e., Kd -2 X 10m0 molJL). The molar ratio of PSA used to elute phage was 25 to 1. The ligand eluate was then amplified and reselected (2 X l0 particles as Underlined sequences are consensus sequences; these indicate motifs that the selected sequences have in common. input in round 2) with ligand and acid to generate 2.3 X iO and 7 X 102 particles, respectively.
We chose to elute the phage particles from immobilized antibody with ligand (PSA) and acid to selectfor PSA-specific sequences [32] . After To selectsequences that were specific to B80 or B87, an immunoblotting assay was performed on nitrocellulose lifts of colonies of cells infected with affinity-selected phage. The fraction obtained by eluting with acid in both rounds of selection did not yield any antibody-specific phage clones. B80-positive clones were seen for both eluants with ligand in the first round. B87-positive clones were only found in the eluant, which was eluted with acid in the first round and ligand in the second round. The resulting peptide insert sequences are shown in Table 3 along with the frequency of appearance of each sequence from among those sequenced. Although it is tempting to speculate that higher frequency of a particular sequence is indicative of preferential binding relative to other sequences, such a conclusion may be premature
and beset with problems of genetically identical siblings picked randomly in the screening step. In all, 66 clones were sequenced.
Many gave the identical DNA sequence, indicating that they were copies of the same clone. Five unique sequences were identified for B80 and eight for B87. Consensus sequences in the Table are underlined and indicate motifs that the selected sequences have in common and require further study that they are equivalent to binding motifs. The most interesting finding was that one consensus sequence was found to be homologous to a linear sequence on PSA, peptide
51-55 (-LGRHS-).
This sequence closely matches the B80-specific peptide sequence
53-59 (-GRHSLFH-)
identified by epitope scanning (Fig. 4) . None of the B87-specific sequences identified by this method is homologous to linear sequences found in PSA. These sequences represent mimotopes, peptide sequences that mimic the natural epitope and are able to bind specifically to the antibody paratope.
The only criteria used to assess homology was sequence alignment performed both manually and by the SEQSEE Eluate Table 2 (1) ANHTRGRPLV (3) WGFDFGFGSS (2) SCLFYNTVCV (3) NEWSDEENGQ (2) B87 sequences SVWGA.ASSPW(3) SRWVRRSSGW (4) SRWSRSRNPR (4) SQWVRRSSGT (4) RPWPRRSSGW (2) SQWRRSSPW (5) SQWVRRSSG (5) RFRQRATIAF (1) Cross-reactive sequences
AFH1TGRIAA (3)
DVRAFHWWGR (5) ADEAFHTVGR (4) PRRRFHTTGA (3) DVPSFHWWGR (3) LVHAFHUGA (3) SVWGMSSPW (1) PSA sequence 45-60 NKSVILLGRHSLFHPE software [33] . Any homologous pattern less than three amino acids was considered insignificant.
Multiple alignments were performed with the inputsequences by using SEQSEE with the rbo.wt matrixwith gap penalties of 10 and extension penalties of 2. In the caseof the B80 binding peptides, those sequences that clusteredtogether as being >40% identical (i.e., the top four sequences in Table 3 ) were aligned separatelywith SEQSEE. Those residuesdisplaying>70% sequence conservationfrom thissetwere used to form a "consensus"sequence.Thus forthe B80 set,the consensus sequence would be TLGRPS***G (where * isany amino acid).In the B87 set,a 70% sequence identity thresholdwas alsoused.These criteria identified the consensus sequence S*W*RRSS. For the sake of simplification, only conserved contiguous residues were underlined in Table 3 . A series of alignments was performed with the eight sequences in the B87 column (Table 3 ) against the PSA sequence (PIR accession A26757) with SEQSEE. The same default scoring matrix and gap penalties were used. The only sequence that yielded any reasonable score was at the N terminus (WECEKHSQPW) of PSA. This particular sequence still required the introduction of two gaps and only two of the most highly conserved residues were matched. By any criteria, this is a poor match. Typically over a stretch of 10 residues, one should expect to find better than 60% sequence identity (with no gaps or breaks) if the match is significant.
The nonspecific or cross-reactive sequences (Table 3 ) appear to be reactive to both mouse antibodies B80 and B87 and may be motifs capable of binding the constant domains of IgG 1. This, however, requires further study.
COMPUTER
MODEL OF PSA
A structural model of the molecule, if not available from x-ray crystallography, can be generated by using proteins of known structure that have a high degree of homology with the antigen. The model can assist in locating highly exposed surface regions and illustrate the spatial relations between various binding or catalytic sites and antibody epitopes. Figure 5 shows the computer-generated homology model of PSA. The catalytic triad for this serine protease-like molecule (His-41, Asp-96, and Ser-71) is shown in white and the location of the ACT binding site, based on what is known about the binding of ACT to chymouypsin, is indicated by the shaded residues. The B80 epitope identified by hexapeptide scanning and phage affinity selection, residues 53-60, is indicated in yellow. It is seen to be on an exposed region of the molecule well away from the ACT binding site. An epitope for B87 was not identified in this study and is likely in an exposed region that is not masked by the binding of ACT or B80 to PSA. Computer models of PSA have been described by Vijinen [34] and Bridon and Dowell [35] . The three-dimensional structure of PSA and glandular kallikrein were modeled on the basis of pKl. Loops unique to PSA were modeled by searching from a database and the structure was refined by energy minimization and molecular dynamics. The resulting model closely resembles the PSA model generated in this study (Fig. 5) . From the location of the binding site of ACT it is apparent that most of the molecule is still exposed and available for binding to antibodies when ACT is complexed to PSA. The B80 epitope (shown in yellow in Fig. 5 ), located in this study, is on a highly exposed region near the N terminus, well away from the ACT binding site. The exact location of the B87 epitope was not determined but the possible epitopes could be limited to exposed regions that are unique to PSA and that do not overlap with the B80 epitope or the ACT binding site.
Discuss#{226}on
In this study we attempt to addressthe issueof immunospecificity of anti-PSA antibodies at the molecular level by characterizing the epitopes recognized by two new mAbs. At least five PSA isomers have been identified with pls ranging from 6.8 to 7.5. This heterogeneity is believed to be caused by differing sialic acid content of the carbohydrate side chains and not by changes in the amino acid sequence [9] . All of this variability means that antibodies directed against specific epitopes may recognize some forms of PSA and not others. There may be epitopes on PSA that are especially sensitive to the conformational changes that occur when the enzyme is converted from precursor to zymogen to enzyme to inactive enzyme. Antibodies directed against conformationally sensitive epitopes may only recognize one of these forms of PSA.
Two anti-PSA mAbs designated B80 and B87 were used in this study. The B80 hybridoma cell line was fused in our laboratory with an anti-HRPO cell line to produce a hybrid hybridoma or quadroma secreting a bispecific mAb with one binding site directed against PSA and the other against HRPO [31] . This useful reagent eliminates the need for biotinylated or secondary antibody-based detection methods and provides us with a probe potentially having the highest specific activity of HRPO-generated signal. Further, this bispecific mAb probe eliminates the high background often created by the secondary polyclonal antibody-enzyme conjugates used in conventional immunoassays. 
